← All companies

FENC · CIK 1211583

What Fennec Pharmaceuticals, Inc. told the SEC could break it.

Fennec is a single-product company: PEDMARK (sodium thiosulfate) is its only product, so any disruption to its commercialization, manufacturing, reimbursement or competitive position would hit the entire business. That concentration sharpens its supply and logistics exposure — it warns its supply sources could be interrupted and may not resume on a reasonable timeline or at acceptable cost, and it relies on third-party logistics providers, distributors and healthcare systems in Turkey and the broader Middle East, where regional instability could disrupt shipping lanes and border crossings. On pricing, to receive federal reimbursement it must offer the VA, DoD and other agencies Federal Supply Schedule pricing capped at the Federal Ceiling Price — at least 24% below the Non-Federal Average Manufacturer Price — constraining what it can net on PEDMARK.

4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.

In its own words

What could break it.

Other disclosures

  • Single-product dependence on PEDMARK/PEDMARQSIhigh

    PEDMARK (sodium thiosulfate) is Fennec's only product, so any disruption to its commercialization, manufacturing, reimbursement, or competitive position would have a material adverse impact on the entire business.

    PEDMARK ® is currently our only product.

    SEC filing →As of 2026

Geographic concentration

  • Geopolitical/logistics disruption in Turkey and the Middle Eastmedium

    Fennec depends on third-party logistics providers, distributors, and healthcare systems in Turkey and the broader Middle East to store, transport, and dispense its products; regional instability and armed conflict could disrupt shipping lanes and border crossings.

    We depend on third-party logistics providers, distributors, and healthcare systems to store, transport, and dispense our products in Turkey and the broader Middle East region.

    SEC filing →As of 2026

Regulatory & policy

  • Federal Ceiling Price / FSS government drug-pricing constraintsmedium

    To receive federal reimbursement, Fennec must offer FSS pricing to the VA, DoD, Coast Guard and Public Health Service at no more than the Federal Ceiling Price — at least 24% below the Non-Federal Average Manufacturer Price — constraining net pricing for PEDMARK.

    FSS pricing to those four federal agencies for covered drugs must be no more than the Federal Ceiling Price (“FCP”), which is at least 24% below the Non-Federal Average Manufacturer Price (“Non-FAMP”) for the prior

Supplier concentration

  • Supply-source interruption risk for its sole productmedium

    Fennec's product supply sources could be interrupted, and if interrupted may not resume within a reasonable timeframe or at acceptable cost, threatening availability of its only product.

    Supply sources could be interrupted from time to time and, if interrupted, supplies may not be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all.

    SEC filing →As of 2026

The hidden graph

Who it depends on, and who depends on it.

Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its customers

  • Norgine Pharma UK Limited

    Our strategy depends in part on the efforts of third party development partners to obtain regulatory approvals and commercialize PEDMARK ® outside the United States, including Norgine Pharma UK Limited (“Norgine”) in Europe and Inpharmus (formerly TRPharm İlaç Sanayi Ticaret A.Ş. and TRPharm FZ-LLC) (“Inpharmus”) in Turkey and Gulf Cooperation Council (“GCC”) countries.

    Cited →
  • Inpharmus (formerly TRPharm)

    Our strategy depends in part on the efforts of third party development partners to obtain regulatory approvals and commercialize PEDMARK ® outside the United States, including Norgine Pharma UK Limited (“Norgine”) in Europe and Inpharmus (formerly TRPharm İlaç Sanayi Ticaret A.Ş. and TRPharm FZ-LLC) (“Inpharmus”) in Turkey and Gulf Cooperation Council (“GCC”) countries.

    Cited →

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch